Huntington’s Disease Treatment Market: By Treatment Type, By Drug Type, By Distribution Channel, and Region Forecast 2020-2031

Huntington’s Disease Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Symptomatic Treatment, and Disease Modifying Therapies), By Drug Type (Tetrabenazine, Deutetrabenazine, Valbenazine, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region Forecast 2020-2031

Huntington’s Disease Treatment Market size was valued at US$ 579.6 million in 2024 and is expected to reach US$ 1,947.3 million by 2031, growing at a significant CAGR of 18.9% from 2025-2031. Moreover, in the USA, the Huntington’s Disease Treatment market size is projected to reach US$ 607.6 million by 2031. Demand for treatment of huntington's disease is led mainly by the increasing demand for therapies to treat chorea symptoms. best-selling medicines tetrabenazine, deutetrabenazine, and valbenazine are prescribed to treat symptoms, with robust demand for symptomatic and disease-modifying therapies. Hospital, retail, and internet pharmacy distribution provide increased access to these medications.

Market opportunities are significant against these constraints of regulatory issues, reimbursement concerns, and cost of production, particularly in Europe and North America, where the prevalence of HD is higher. Also, expansion in emphasis on homecare and ambulatory therapies with the government's facilitation are expanding access to treatment. Drug delivery technological advancements, such as handheld and green devices, are also making market growth due to their efficiency and sustainability during treatment. As it is continually ongoing, advances in disease-altering therapy also bring unique treatment and better patient care in a growing market that ensures sustained long-term growth.

Facts and Figures

  • Huntington’s Disease affects approximately 3 to 7 per 100,000 people globally. In the United States, around 30,000 individuals are living with HD, with 150,000 individuals at risk due to family history. The prevalence is lower in Asia, where fewer cases are reported.
  • The gene therapy AMT-130, developed by uniQure, is currently in clinical trials. As of 2023, Phase 1/2 trials for AMT-130 have been completed, enrolling 39 patients. The therapy aims to modify the course of the disease, offering a promising disease-modifying treatment. It is part of the growing focus on gene therapies to treat genetic disorders like Huntington’s Disease.

Key Takeaways

  • The global prevalence of HD is estimated at 4.88 per 100,000 persons, with higher rates in Europe (6.37 per 100,000) and North America (8.87 per 100,000), while Asia and Africa report significantly lower rates (0.25 to 0.41 per 100,000).
  • The global incidence of HD is 0.48 cases per 100,000 person-years, with advancements in genetic testing contributing to increased diagnoses and recognition of de novo mutations.

Key Developments:

  • May 2023: Neurocrine Biosciences' drug, valbenazine, showed substantial improvement in managing Huntington's disease-associated chorea during a Phase 3 trial. The anticipated approval and launch of similar drugs are expected to significantly drive market growth.
  • September 2023: Neurocrine Biosciences announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for INGREZZA (valbenazine) oral granules, a new sprinkle formulation for treating Huntington's disease-associated chorea.
  • April 2023: Prilenia Therapeutics revealed the top-line results from the Phase 3 PROOF-HD clinical trial at the American Academy of Neurology (AAN) Annual Meeting, examining the safety and effectiveness of pridopidine in individuals with Huntington's disease.
  • December 2022: The U.S. FDA accepted the supplemental new drug application for valbenazine, developed by Neurocrine Biosciences, as a treatment for chorea associated with Huntington’s disease.

Huntington’s Disease Treatment Market Segmentation:

Based on the treatment type:

  • Symptomatic Treatment
  • Disease Modifying Therapies

The symptomatic treatment segment dominates the market, as it primarily addresses the management of chorea and other physical and cognitive symptoms. Drugs like tetrabenazine, deutetrabenazine, and valbenazine are widely used to alleviate motor dysfunction, providing symptomatic relief and improving quality of life for patients.

Based on the drug type:

  • Tetrabenazine
  • Deutetrabenazine
  • Valbenazine
  • Others

The tetrabenazine segment dominates the market. Tetrabenazine is widely used to manage chorea, the most common motor symptom of huntington’s disease. Its ability to effectively reduce involuntary movements has made it a preferred treatment option, driving significant market demand, particularly for patients in homecare settings.

Based on the distribution channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Hospital Pharmacies dominate the market. These pharmacies are preferred due to their proximity to healthcare professionals who can monitor patient progress closely. Hospital pharmacies ensure a continuous supply of prescribed medications, including tetrabenazine, deutetrabenazine, and valbenazine, which are crucial for managing symptoms in an inpatient setting.

Huntingtons Disease Treatment Market Summary

Study Period

2025-2031

Base Year

2024

CAGR

18.9%

Largest Market

North-America

Fastest Growing Market

Asia-Pacific

Huntington's Disease Treatment Market Dynamics

Drivers

The market is primarily driven by the rising prevalence of HD, particularly in North America and Europe, where it affects approximately 30,000 people in the U.S. and up to 10 out of 100,000 people in Europe. As the patient population grows, the demand for effective treatments continues to rise. Advancements in disease-modifying therapies, such as gene therapies and neuroprotective drugs, offer the potential to slow or halt disease progression, fueling market growth. Symptomatic treatments like tetrabenazine, deutetrabenazine, and valbenazine, which help manage chorea, remain crucial in enhancing patients' quality of life. The increasing adoption of homecare solutions, where patients can self-administer treatments, is another key factor driving the market, as it reduces hospital stays. Biopharmaceutical innovations, including personalized medicines and biologics, are expanding treatment options.

In addition, government funding and research initiatives, especially from organizations like the NIH, are accelerating the development of new therapies. Improvements in genetic testing enable earlier diagnosis and better disease management. Regulatory approvals for new treatments, such as valbenazine, continue to strengthen market momentum, further contributing to the growth of the HD treatment market.

Restraints

The market faces several significant restraints that hinder its growth. One of the primary challenges is the high cost of the treatments, particularly the new ones like the gene therapies and disease-modifying therapies. They are usually lengthy and costly and therefore out of reach for the majority of the patients, mostly in under-funded healthcare settings. Second, symptomatic therapy for HD patients is present, yet there is no treatment option for HD at present, and the lack of disease-modifying drugs that reverse the pathologic basis of the illness limits treatment and patient satisfaction. Regulatory barriers and prolonged approval windows for new treatments also delay market growth, as enormous clinical trials and safety assessments must happen before approval.

Moreover, delayed diagnosis due to insufficient knowledge of HD among healthcare professionals could result in interventions at a later point in the disease, reducing the effectiveness of available interventions. Ethical concerns over genetic testing and psychological effects could discourage some from seeking enrollment in diagnosis and treatment, hence restricting the number of patients. Finally, compliance on the part of patients with chronic treatment regimens is a factor as predictive nature of the disease and side effects due to therapy will dictate punctual application of regular therapy.

Opportunities

The market presents several key opportunities that can drive growth during the forecast period. Development of disease-modifying drugs, which can reverse or even stop the progression of the disease, and clinical research into gene and RNA therapies are starting to produce auspicious results. Also, the expanding trend of personalized medicine offers an opportunity to formulate treatments based on individual genetic patterns, potentially optimizing treatment impact and benefit to the patient. Furthermore, further research investments and cooperation among biotech firms, academia, and government agencies are driving HD treatment innovation towards the hopes of breakthrough treatments. Growing awareness of HD is also an opportunity, with rising diagnoses translating to better intervention and greater effectiveness of existing treatments.

Moreover, expanding access to treatment globally, focusing on the BRIC and other emerging economies, is a huge growth opportunity in the wake of unprecedented, untapped patient pools in Asian and Latin American markets. Besides that, the quick approval of new therapies, such as gene therapies, will assist in bringing innovative medicines to the market faster, accelerating the industry's growth at a quicker rate. The treatment of huntington's disease is going through some significant trends that are shaping its future development.

Trends

The market is experiencing several significant trends that are shaping its future growth. One key trend is the growing focus on gene therapy, with companies like Neurocrine Biosciences and Prilenia Therapeutics developing promising treatments targeting the genetic mutations responsible for HD. This approach is expected to bring more disease-modifying therapies to market. Additionally, there is a shift towards personalized medicine, where treatments are tailored to individual patients based on their genetic makeup and disease progression, improving treatment outcomes. Another trend is the increasing use of combination therapies, which combine symptomatic treatments with emerging therapies to better manage both motor and cognitive symptoms of HD.

Furthermore, advancements in biomarkers and diagnostic tools are enabling earlier detection of the disease, allowing for more effective interventions and better patient management. The expansion of treatment access to underserved regions, particularly in Asia and Latin America, is also contributing to market growth. Lastly, regulatory support for innovative therapies is accelerating the development and availability of new treatments, especially gene therapies, through fast-track approvals and breakthrough designations.

Huntingtons Disease Treatment Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2025-2031

Market Size in 2024

US$ 579.6 million

Market Size in 2031

US$ 1,947.3 million

Market CAGR

18.9%

By Treatment Type

  • Symptomatic Treatment
  • Disease Modifying Therapies

By Drug Type

  • Tetrabenazine
  • Deutetrabenazine
  • Valbenazine
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Analyst Review

The market is poised for significant growth, driven by increasing disease prevalence and advancements in treatment options. North America dominates the market, accounting for a significant share due to the high HD prevalence, robust healthcare infrastructure, and ongoing drug approvals like Valbenazine. Europe follows closely, with increasing regulatory collaborations propelling market growth. However, the Asia Pacific region is expected to experience the fastest CAGR, attributed to rising disease awareness and improving healthcare access, especially in developing countries like China and India.

Key developments include the advancement of gene therapies, with AMT-130 (uniQure) currently in Phase 1/2 trials, showing potential for disease-modifying treatments. Symptomatic treatments, including tetrabenazine, deutetrabenazine, and valbenazine, continue to be widely used to manage chorea, the most common symptom. The market faces challenges from high treatment costs and regulatory hurdles but is supported by opportunities in personalized medicine and expanding market access, particularly in emerging regions. The continuous innovations in drug delivery and gene therapy hold the promise of transforming patient care.

Key Features of the Report

  • The huntington's disease treatment market report provides granular level information about the market size, regional market share, historic market (2020-2024), and forecast (2025-2031)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

The huntington’s disease treatment market size was valued at US$ 579.6 million in 2024 and is projected to grow at a CAGR of 18.9% from 2025-2031.

• Rising Prevalence and Awareness • Advancements in Disease-Modifying Therapies • Government Support and Funding

• Regulatory Support for Fast-Tracking Innovative Therapies • Development of Disease-Modifying Therapies • Growing Research Collaborations

The market reports cover the treatment type, drug type, distribution channel, and region segment.

Asia Pacific is the fastest-growing region in the market.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1.Executive Summary
2.Global Huntington’s Disease Treatment Market Introduction 
2.1.Global Huntington’s Disease Treatment Market  - Taxonomy
2.2.Global Huntington’s Disease Treatment Market  - Definitions
2.2.1.Treatment Type
2.2.2.Drug Type
2.2.3.Distribution Channel
2.2.4.Region
3.Global Huntington’s Disease Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Huntington’s Disease Treatment Market Analysis, 2020 - 2024 and Forecast 2025 - 2031
4.1.  Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Huntington’s Disease Treatment Market  By Treatment Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
5.1. Symptomatic Treatment
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Disease Modifying Therapies
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Huntington’s Disease Treatment Market  By Drug Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
6.1. Tetrabenazine
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Deutetrabenazine
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Valbenazine
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Huntington’s Disease Treatment Market  By Distribution Channel, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Huntington’s Disease Treatment Market  By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
9.1. Treatment Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Symptomatic Treatment
9.1.2.Disease Modifying Therapies
9.2.  Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Tetrabenazine
9.2.2.Deutetrabenazine
9.2.3.Valbenazine
9.2.4.Others
9.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
10.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Symptomatic Treatment
10.1.2.Disease Modifying Therapies
10.2.  Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Tetrabenazine
10.2.2.Deutetrabenazine
10.2.3.Valbenazine
10.2.4.Others
10.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
11.Asia Pacific (APAC) Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
11.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Symptomatic Treatment
11.1.2.Disease Modifying Therapies
11.2.  Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Tetrabenazine
11.2.2.Deutetrabenazine
11.2.3.Valbenazine
11.2.4.Others
11.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
12.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Symptomatic Treatment
12.1.2.Disease Modifying Therapies
12.2.  Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Tetrabenazine
12.2.2.Deutetrabenazine
12.2.3.Valbenazine
12.2.4.Others
12.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Huntington’s Disease Treatment Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million)
13.1. Treatment Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Symptomatic Treatment
13.1.2.Disease Modifying Therapies
13.2.  Drug Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Tetrabenazine
13.2.2.Deutetrabenazine
13.2.3.Valbenazine
13.2.4.Others
13.3.  Distribution Channel Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Lupin
14.2.2.Novartis AG
14.2.3.H. Lundbeck A/S
14.2.4.Prilenia Therapeutics
14.2.5.Hikma Pharmaceuticals PLC
14.2.6.Bausch Health Companies Inc.
14.2.7.Neurocrine Biosciences, Inc.
14.2.8.Dr. Reddy’s Laboratories Ltd.
14.2.9.Teva Pharmaceutical Industries Ltd.
14.2.10.Sun Pharmaceutical Industries, Inc.
15. Research Methodology 
16. Appendix and Abbreviations 

Key Market Players

  • Lupin
  • Novartis AG
  • H. Lundbeck A/S
  • Prilenia Therapeutics
  • Hikma Pharmaceuticals PLC
  • Bausch Health Companies Inc.
  • Neurocrine Biosciences, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries, Inc.

Related Industry Reports